Hanmi Pharmaceutical said Thursday that its Chinese subsidiary, Beijing Hanmi Pharmaceutical Co., surpassed annual sales of $290 million for the first time since its establishment.
According to the company, Beijing Hanmi posted $290 million in revenue and $56 million in operating profit in 2025. Revenue rose 4.4% from a year earlier, while operating profit fell 5.5%.
Backed by its stable earnings performance, Beijing Hanmi has continued increasing its financial contribution to Hanmi Pharmaceutical. Hanmi Pharmaceutical owns a 73.68% stake in the Chinese subsidiary and received approximately $6.5 million in dividend income last year.
Cumulative dividends paid since 2009 have reached roughly $99 million.
For its 2026 regular dividend, Beijing Hanmi applied a 50% payout ratio based on net profit, resulting in a total dividend of about $28 million, of which approximately $21 million was allocated to Hanmi Pharmaceutical.
The company said those dividend resources are being used as a key financial foundation to support innovative drug research and development and global business expansion. Beijing Hanmi’s stable cash flow also strengthens the group’s overall financial health and supports long-term growth investments.
The subsidiary has responded flexibly to China’s rapidly changing policy environment, including the government’s volume-based procurement (VBP) system, turning regulatory pressure into an opportunity to strengthen competitiveness, the company said.
Beijing Hanmi currently operates a sales and marketing network covering more than 9,000 hospitals and over 200,000 medical professionals across China.
The company is also accelerating efforts to secure next-generation growth drivers based on its established products, including constipation treatment “Ritong,” cough suppressant and expectorant “Yianping,” and cough medicine “Yitanjing.”
Leveraging its strengths in pediatrics and respiratory care, Beijing Hanmi is expanding its China-focused pipeline into chronic disease areas such as hypertension and diabetes to strengthen future growth momentum.
A Beijing Hanmi official said the company has become a successful model supporting Hanmi Group’s global management strategy and continues to create synergies within the group.
“We will continue pursuing stable growth through product strategies aligned with local market needs while strengthening the group’s future competitiveness,” the official said.
Beijing Hanmi Pharmaceutical, established in 1996, is Hanmi Pharmaceutical’s Chinese subsidiary and has built a stable growth foundation in the Chinese market through localized drug development and distribution networks.